TY - JOUR T1 - The Role of <sup>18</sup>F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 64S LP - 73S DO - 10.2967/jnumed.108.057257 VL - 50 IS - Suppl 1 AU - Julie K. Schwarz AU - Perry W. Grigsby AU - Farrokh Dehdashti AU - Dominique Delbeke Y1 - 2009/05/01 UR - http://jnm.snmjournals.org/content/50/Suppl_1/64S.abstract N2 - For locally advanced cervical cancer, the current literature supports the use of 18F-FDG PET for assessing treatment response 3 mo after the completion of concurrent chemoradiation. 18F-FDG PET can provide reliable long-term prognostic information for these patients and, in the future, may be used to guide additional therapy. Investigational areas include the use of 18F-FDG PET for monitoring response during radiotherapy and chemotherapy in the metastatic and neoadjuvant settings. For ovarian masses, the performance of 18F-FDG PET in the detection of borderline tumors is limited, and the presence of physiologic 18F-FDG uptake in normal ovaries of premenopausal women poses another limitation. Preliminary data suggest that the performance of 18F-FDG PET and 18F-FDG PET/CT is superior to that of CT alone in initial staging, but the sensitivity of both in the detection of carcinomatosis is limited. Preliminary data also suggest that 18F-FDG PET may be promising for early prediction of response to chemotherapy and for prediction of response after the completion of chemotherapy. 18F-FDG PET and 18F-FDG PET/CT are most helpful in the evaluation of patients with suspected recurrent ovarian carcinoma, especially when CA-125 levels are rising and CT findings are normal or equivocal. PET and CT are complementary, and PET/CT should be used when available. Preliminary data suggest that the addition of 18F-FDG PET/CT to the evaluation of these patients changes management in approximately a third and reduces overall treatment costs by accurately identifying patients who will or will not benefit from surgery. ER -